# Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS)

> **NCT00050154** · PHASE2 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 82 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** ZARNESTRA, tipifarnib, R115777

## Key facts

- **NCT ID:** NCT00050154
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** —
- **Final completion:** 2006-05
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2010-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00050154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00050154, "Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00050154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*